Belma Pehlivanović Kelle

Prof. Dr. Belma Pehlivanović Kelle

University of Sarajevo, Faculty of Pharmacy, Department of Pharmacology and Clinical Pharmacy
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 June 2020 in Medical Archives
Verified
Journal Article
Open access
NZNermina Ziga-Smajic
Nermina Ziga-Smajic
SSSelma Skrbo
Selma Skrbo
SMSamija Muratovic
Samija Muratovic
Belma Pehlivanović KelleBelma Pehlivanović Kelle
Belma Pehlivanović Kelle
DLDina Lagumdzija
Dina Lagumdzija
Naida Omerović ĆorovićNaida Omerović Ćorović
Naida Omerović Ćorović
Hyperuricemia is an independent risk factor for the development of many diseases. The aim of this paper is to compare the effects of allopurinol and febuxostat on the values of triglycerides and uric acid in hyperuricemic patients. This was a pharmacological-clinical retrospective-prospective study. The research sample comprised 50 examinees of both genders and different ages who were undergoing allopurinol (100 mg/day) or febuxostat (80 mg/day) therapy. Statistical Product and Service Solutions (SPSS) Software and Microsoft Excel were used for statistical analysis. Examinees who were treated with allopurinol had a statistically significant decrease in uric acid concentrations (by 126.28 ± 20.36 μmol/l) at the end of the observation compared to the initial values (p = 0.006). Examinees who were treated with febuxostat had a statistically significant decrease in uric acid concentrations (by 252.80 ± 94.17 μmol/l) at the end of the observation compared to the initial values (p = 0.001). The initial value of triglycerides was 1.58 ± 0.64 mmol/l in allopurinol-treated examinees, and 1.60 ± 0.52 mmol/l in febuxostat-treated examinees. After three and six months of allopurinol use, there was a statistically significant increase in triglyceride values (p = 0.046 and p = 0.042, respectively). A statistically significant decrease in triglyceride values (by 0.16 ± 0.10 mmol/l) was noted after three months of febuxostat use (p = 0.012). The results of this research confirmed the previous findings and pointed out the positive pharmacological effects of allopurinol and febuxostat.

23 January 2021 in Journal of Pharmaceutical Research International
Verified
Journal Article
Closed access
PDF file
Belma Pehlivanović KelleBelma Pehlivanović Kelle
Belma Pehlivanović Kelle
ČKČaklovica Kenan
Čaklovica Kenan
LDLagumdžija Dina
Lagumdžija Dina
Naida Omerović ĆorovićNaida Omerović Ćorović
Naida Omerović Ćorović
ŽNŽiga Smajić Nermina
Žiga Smajić Nermina
BFBečić Fahir
Bečić Fahir
The pursuance of novel antimicrobial and anti-inflammatory agents has been expanding due to a significant need for more efficient pharmacotherapy of various infections and chronic diseases. During the last decade, pharmacokinetics, pharmacodynamics and pharmacological properties of curcumin have been extensively studied. The aim of the present study was to evaluate the antibacterial activity of curcumin against both Gram-positive and Gram-negative bacteria as well as its antifungal activity by using in vitro agar well diffusion assay. Moreover, the anti-inflammatory activity of curcumin was determined with in vitro assay of inhibition of protein denaturation. Results demonstrated wide antimicrobial activity of curcumin upon all of the test bacteria and fungi. The strongest activity of curcumin was observed at a concentration of 0.50 mg/ml against S. aureus, L. monocytogenes, E. coli, P. aeruginosa and C. albicans, resulting in a maximum zone of inhibition of 14.7 mm, 14.3 mm, 13.7 mm, 10.7 mm and 10.7 mm, respectively. Findings suggested that the antimicrobial activity of curcuminis dependent upon the concentrations. Furthermore, results demonstrated high effectiveness of curcumin compared to standard acetylsalicylic acid in inhibiting heat-induced protein denaturation, which activity is also depended upon the concentrations. The present study emphasises the potential application of curcumin as a natural antimicrobial and anti-inflammatory agent. However, findings of this study are restricted to in vitro assays and consideration should be given to conducting a study involving wider dose range test substances as well as including further research on in vivo models.

1 October 2024 in Biomolecules and Biomedicine
Verified
Journal Article
Open access
PDF file
DLDina Lagumdzija
Dina Lagumdzija
AMAida Hamzić Mehmedbašić
Aida Hamzić Mehmedbašić
DJDzan Ahmed Jesenkovic
Dzan Ahmed Jesenkovic
BKBakir Kudić
Bakir Kudić
DKDina Kapic
Dina Kapic
ACAida Kulo Cesic
Aida Kulo Cesic
The objective of this study was to confirm the effects of curcumin and to investigate the effects of its combination with a reduced dose of rosuvastatin in an adenine-induced model of chronic kidney disease (CKD) and associated dyslipidemia in rats. Renal function and morphology, as well as lipid status, were assessed using laboratory parameters and histopathological analysis. Male Wistar rats (n=36) randomly divided into six groups, were treated for 24 days: normal control (standard diet), CKD control (adenine diet, 0.75% w/w adenine-supplemented diet), curcumin (100 mg/kg/day + adenine diet), rosuvastatin minimal therapeutic dose (MTD) (5 mg/day + adenine diet), rosuvastatin reduced dose (RD, 25% of rosuvastatin MTD + adenine diet), and rosuvastatin RD + curcumin (25% of rosuvastatin MTD + curcumin 100 mg/kg/day + adenine diet) group. While rosuvastatin alone showed only antilipemic action, both curcumin alone and its combination with a reduced dose of rosuvastatin showed better renal protection with lower serum creatinine levels and milder renal morphological alterations, as well as better antilipemic action with lower levels of triglycerides, very low-density lipoprotein (VLDL), and low-density lipoprotein (LDL) cholesterols compared with the levels in CKD control rats. Treatment with curcumin alone also resulted in a significantly higher estimated glomerular filtration rate, lower uric acid levels, and higher high-density lipoprotein (HDL) cholesterol, while the combined therapy additionally resulted in higher serum albumin levels, lower total cholesterol, and both atherogenic and coronary risk indexes compared with CKD control rats. The results of this study confirmed the beneficial effects of curcumin alone and provided new evidence for the beneficial effects of its combination with a reduced dose of rosuvastatin in rats with CKD and associated dyslipidemia.

12 May 2021
Verified
Book Chapter
Closed access
PDF file
ASAida Sapcanin
Aida Sapcanin
EPEkrem Pehlic
Ekrem Pehlic
SKSelma Korac
Selma Korac
EREmina Ramic
Emina Ramic
Belma Pehlivanović KelleBelma Pehlivanović Kelle
Belma Pehlivanović Kelle

1 June 2021
Verified
Book Chapter
Closed access
PDF file
Belma Pehlivanović KelleBelma Pehlivanović Kelle
Belma Pehlivanović Kelle
KČKenan Čaklovica
Kenan Čaklovica
AŠAida Šapčanin
Aida Šapčanin
DLDina Lagumdžija
Dina Lagumdžija
Naida Omerović ĆorovićNaida Omerović Ćorović
Naida Omerović Ćorović
FBFahir Bečić
Fahir Bečić

15 December 2025 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
TSTarik Suljic
Tarik Suljic
BKBakir Kudic
Bakir Kudic
Belma Pehlivanović KelleBelma Pehlivanović Kelle
Belma Pehlivanović Kelle
AHAida Hamzic-Mehmedbasic
Aida Hamzic-Mehmedbasic
JMJasminka Mujic
Jasminka Mujic
ACAida Kulo Cesic
Aida Kulo Cesic
The burden of nephrotoxicity and ototoxicity consequences caused by gentamicin warrants preventive therapeutic measures. Our aim was to evaluate combined and potentially synergistic effects of rosuvastatin and curcumin, both possessing anti-inflammatory and antioxidant properties, compared to their monotherapies in a gentamicin-induced model of nephrotoxicity and ototoxicity. In a randomized, controlled study, 36 male Wistar rats were allocated to six groups and treated for 5 days: negative control group received solvent, model group gentamicin (100 mg/kg, intraperitoneally), treatment groups gentamicin and via orogastric tube either standard-dose rosuvastatin (5 mg/day), reduced-dose rosuvastatin (1.25 mg/day), curcumin (100 mg/kg), or combination of reduced-dose rosuvastatin and curcumin. Human rosuvastatin doses were converted to rat doses using the conversion factor of 6.2. Functional outcomes evaluated by Preyer pinna reflex for hearing and a vestibular battery test were complemented by renal and cochlear histology, biochemical biomarkers of injury, inflammation, and oxidative stress. Gentamicin induced proximal tubular necrosis and cochlear and vestibular damage. Compared to monotherapies, combination therapy significantly preserved renal architecture, improved renal biomarkers, reduced early inflammatory biomarkers, preserved cochlear architecture and drove vestibular protection. It also alleviated gentamicin-induced cardiotoxicity. Rosuvastatin provided stronger auditory protection, with reduced-dose rosuvastatin superior to standard-dose in preserving vestibular function. Bliss independence modelling showed that combined therapy synergistically inhibited kidney injury and inflammation. In conclusion, the combination of reduced-dose rosuvastatin and curcumin outperforms both monotherapies in alleviating gentamicin-induced nephrotoxicity, audiotoxicity and vestibulotoxicity, whilst synergistically attenuating nephrotoxicity and early-phase inflammation in rats. These findings highlight promising preventive strategies against aminoglycoside nephrotoxicity and ototoxicity.